Odyssey Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
ODTX$20.00+4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands) (unaudited)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(144,109) | $(115,132) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 3,223 | 3,754 |
| Loss from disposal of property and equipment | 602 | 1,160 |
| Right-of-use asset impairment expense | — | 5,440 |
| Amortization (accretion) of premium (discount) on marketable securities | 115 | (864) |
| Stock-based compensation expense | 16,196 | 11,581 |
| Non-cash lease expense | 2,663 | 2,349 |
| Change in fair value of contingent consideration and warrant liability | 12,220 | (4,386) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (2,495) | (1,123) |
| Other non-current assets | (854) | 5,057 |
| Accounts payable | 338 | 313 |
| Lease liabilities | (3,780) | (3,014) |
| Accrued expenses and other current liabilities | (1,204) | (9,274) |
| Net cash used in operating activities | (117,085) | (104,139) |
| Cash flows from investing activities: | ||
| Maturities of marketable securities | 113,675 | 70,950 |
| Purchases of marketable securities | (246,489) | (185,772) |
| Proceeds from sale of property and equipment | 302 | 357 |
| Purchases of property and equipment | (838) | (1,004) |
| Net cash used in investing activities | (133,350) | (115,469) |
| Cash flows from financing activities: | ||
| Proceeds from the exercise of common stock options | 1,389 | 261 |
| Proceeds from the exercise of common stock warrants | — | 72 |
| Principal payments on finance leases | (117) | (107) |
| Proceeds from the issuance of common stock upon IPO, net of offering costs | 288,194 | — |
| Proceeds from the issuance of convertible preferred stock, net of issuance costs | — | 209,479 |
| Net cash provided by financing activities | 289,466 | 209,705 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 166 | 291 |
| Increase (decrease) in cash, cash equivalents and restricted cash | 39,197 | (9,612) |
| Cash, cash equivalents and restricted cash, beginning of period | 44,897 | 62,346 |
| Cash, cash equivalents and restricted cash, end of period | $84,094 | $52,734 |
| Cash and cash equivalents, end of period | $80,641 | $49,524 |
| Restricted cash, included in other non-current assets, end of period | 3,453 | 3,210 |
| Total cash, cash equivalents and restricted cash, end of period | $84,094 | $52,734 |
| Supplemental cash flow information: | ||
| Cash paid for income taxes | $251 | $164 |
| Cash paid for interest | $42 | $5 |
| Supplemental disclosure of non-cash financing and investing activities: | ||
| Offering costs included in accounts payable and accrued expenses and other current liabilities | $20 | $— |
| Right-of-use assets obtained in exchange for new finance lease liabilities | $278 | $— |
| Conversion of preferred stock and preferred stock warrants into common stock and common stock warrants, upon initial public offering | $703,630 | $— |
| Conversion of preferred stock into common stock | $— | $7,366 |
| Property and Equipment in accounts payable and accrued expenses and other current liabilities | $179 | $— |
| Unrealized loss on marketable securities | $1,221 | $153 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.